Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.
about
Pregnancy-Associated Changes in Pharmacokinetics: A Systematic ReviewHIV protease inhibitors, indinavir or nelfinavir, augment antimalarial action of artemisinin in vitroPostpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals.Atazanavir pharmacokinetics with and without tenofovir during pregnancyNelfinavir and its active metabolite, hydroxy-t-butylamidenelfinavir (M8), are transferred in small quantities to breast milk and do not reach biologically significant concentrations in breast-feeding infants whose mothers are taking nelfinavir.Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum.Postpartum viral load rebound in HIV-1-infected women treated with highly active antiretroviral therapy: AIDS Clinical Trials Group Protocol A5150.HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury.The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy.A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction.Risk of congenital cytomegalovirus infection among HIV-exposed uninfected infants is not decreased by maternal nelfinavir use during pregnancy.Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy.Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimizationPharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum.Drug labeling and exposure in neonatesPharmacokinetic optimization of antiretroviral therapy in pregnancy.HIV protease inhibitors in pregnancy : pharmacology and clinical use.Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya.Factors Associated with Lower Respiratory Tract Infections in HIV-Exposed Uninfected Infants.
P2860
Q28109657-67E06CDB-6931-40A1-9A12-A0FD3D98611FQ33578923-E34F73A3-9AE0-4084-B817-D1960D498809Q33749434-1D6D5EDA-CA2F-450F-913F-006BF9A533BAQ34429204-F413DDAD-8499-4C03-A4B6-1B1FC20BE975Q35074548-CEF7D43D-00A0-4F9A-98D6-217750172130Q35364022-E614113B-F58C-4633-9A25-B3713B704996Q35388475-1EE9025B-8AA2-4182-8303-09C22344FF1BQ35583120-C2753B23-2E07-45B0-844E-ED04BF0396A3Q35852627-6EA98E2E-DFD3-4985-AAB6-D24D26B9DD42Q36243467-B284D197-E287-4459-9047-9B1515DEF9F5Q36712344-BCBBFA08-EB31-4615-A6BA-222AEB099C08Q36757599-E67DA1A9-3217-405C-AC6E-98A143C8F0E3Q36930395-7AC8022C-4638-4063-96FB-6ECF367E2F22Q37298637-600E4733-A6C2-412E-B006-EDA598F19601Q37319793-8AC7CB9D-D209-4DD2-8B93-CAFBDDE35A84Q37591097-9B784BFD-D155-4855-A263-3A3DB202F8E4Q38047214-C32D9D2D-E42F-4999-87ED-304291B21E20Q38081072-5EB44633-D1C6-480B-A04D-9CFAC6E1841AQ46524400-C60351FD-2CC9-42FD-9032-9C82C2908065Q52604811-FF61245F-7D91-4A13-A823-67363A25DED6
P2860
Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Pharmacokinetics and safety of ...... ls Group (PACTG) Protocol 353.
@ast
Pharmacokinetics and safety of ...... ls Group (PACTG) Protocol 353.
@en
type
label
Pharmacokinetics and safety of ...... ls Group (PACTG) Protocol 353.
@ast
Pharmacokinetics and safety of ...... ls Group (PACTG) Protocol 353.
@en
prefLabel
Pharmacokinetics and safety of ...... ls Group (PACTG) Protocol 353.
@ast
Pharmacokinetics and safety of ...... ls Group (PACTG) Protocol 353.
@en
P2093
P2860
P356
P1433
P1476
Pharmacokinetics and safety of ...... ls Group (PACTG) Protocol 353.
@en
P2093
E Capparelli
L M Mofenson
M D Hughes
P2860
P304
P356
10.1310/HCT0902-115
P577
2008-03-01T00:00:00Z